NLTX

Neoleukin Therapeutics (NLTX)

Neoleukin Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NLTX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/08/10	05 : 15	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/08/09	20 : 31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/08/07	20 : 31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/06/21	21 : 32	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/06/19	03 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/06/18	03 : 37	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/06/18	03 : 37	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/06/18	03 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/06/18	03 : 35	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/06/18	03 : 35	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/06/03	20 : 31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/05/11	05 : 14	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/05/10	20 : 31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/05/07	19 : 20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/04/27	03 : 34	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/04/27	03 : 33	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/04/27	03 : 33	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/04/23	05 : 44	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/04/03	04 : 43	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/03/19	05 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/03/19	05 : 04	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/03/15	09 : 54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/03/15	09 : 53	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/03/15	09 : 51	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/03/08	06 : 29	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/03/05	08 : 20	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/03/04	21 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/02/22	06 : 07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/02/21	06 : 16	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:NLTX	Neoleukin Therapeutics Inc
2024/02/15	08 : 05	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:NLTX	Neoleukin Therapeutics Inc